Biochemical and Biophysical Research Communications
Autocrine Semaphorin3A signaling is essential for the maintenance of stem-like cells in lung cancer
Introduction
In spite of the development of new treatments, lung cancer is currently the third leading cause of cancer death [1]. Therefore, a detailed understanding of lung cancer biology is essential for improvements in diagnosis and therapeutic strategies. There is increasing evidence that a small population of cells called cancer stem-like cells (CSC), which have stem cell-like properties including self-renewal, multi-potency, and drug-resistance, exist in many types of cancers [2], [3], [4]. CSCs have been shown to be responsible for tumorigenesis, indicating that their eradication could prevent tumor development and recurrence. Therapeutic strategies targeting CSCs have been reported to decrease tumor growth or prolong tumor latency in several tumor models [4], [5], [6], [7], [8]. However, signaling pathways that regulate the maintenance of CSCs remain to be elucidated.
Semaphorin molecules, which were originally discovered as axonal guidance factors, exhibit their activity by binding to plexin receptors and neuropilin co-receptors [9]. Recently, the regulatory role of semaphorin signaling in various diseases including immunological or bone disorders and cancer became clear [10]. Several groups demonstrated that Semaphorin3A (Sema3a) can act as a tumor suppressor by inhibiting angiogenesis, migration, metastasis, and cell proliferation [11], [12], [13]. However, there are contradictory reports that show that Sema3a promotes malignancy by increasing angiogenesis and migration [14], [15]. A recent study revealed that activation of the mutant, but not wild type, PLEXA1 by Sema3a increased the invasive and proliferative capacity of pancreatic cancer cells [16]. These conflicting results make it difficult to understand the role of Sema3a in tumor biology and further studies are needed to reveal the mechanism by which Sema3a exhibits tumor-suppressive or -promoting ability in different tumor microenvironments.
Previously we reported that shRNA mediated knockdown of Sema3a in Lewis lung carcinoma (LLC) cells suppressed its proliferative capacity and tumorigenicity [17], [18]. In this study, we examined the effect of Sema3a knockdown on stem cell-like properties of LLC-derived cancer stem-like cells (LLC-stem) to understand the role of Sema3a signaling in lung cancer.
Section snippets
Mice
Male C57BL/6J mice (5 weeks) used as recipients were provided from SLC (Japan). All animal experiments were approved by the Committee on Animal Experimentation of Niigata University of Pharmacy and Applied Life Sciences and performed in compliance with the University's Guidelines for the Care and Use of Laboratory Animals.
Cell culture
LLC-GFP cells were provided by AntiCancer Japan. LLC-stem cells were maintained in DMEM/F12 (Sigma-Aldrich) containing B27/RA(−) (Life technologies), 10 μg/ml EGF
Loss of tumorigenicity following Sema3a knockdown
By culturing tumor cells under nonadherent conditions, CSCs with sphere-forming and tumorigenic capacity have been established [19], [20], [21]. In this study, we used LLC cells that constitutively express GFP (LLC-GFP). When LLC-GFP cells were cultured on ultra-low attachment plates in DMEM/F12 containing 10 ng/ml FGF2, 10 ng/ml EGF, and B27 without retinoic acid (RA) for 1 week, the cells formed spheroid structures and were designated as LLC-stem cells. Scramble shRNA or Sema3a shRNA
Discussion
Several signaling pathways are associated with the maintenance of CSCs, the cells from which tumors originate [5], [8], [24], [25], [26]. This is the first known study demonstrating that autocrine Sema3a signaling plays a critical role in maintaining the self-renewal capacity of CSCs. Sema3a is a bivalent factor; serving as either tumor-inhibitory or tumor-promoting factor depending on tumor microenvironment. Our studies show that Sema3a promotes malignancy in lung cancer. Recently, Sema3f was
Author contribution
Daisuke Yamada and Takehiko Maeda conceived and designed the experiments. Daisuke Yamada and Kensuke Takahashi performed the experiments. Daisuke Yamada and Kensuke Takahashi analyzed data. Daisuke Yamada and Takehiko Maeda contributed reagents/materials/analysis tools. Daisuke Yamada, Kensuke Takahashi, Kohichi Kawahara and Takehiko Maeda wrote the paper.
Conflict of interest
The authors declare no conflict of interest.
Acknowledgements
This work was supported by JSPS KAKENHI Grant Number 15K18449 and 15K08682.
References (29)
- et al.
TGF-beta promotes heterogeneity and drug resistance in squamous cell carcinoma
Cell
(2015) - et al.
Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity
Cancer Cell
(2013) - et al.
mTORC1 is a critical mediator of oncogenic Semaphorin3A signaling
Biochem. Biophys. Res. Commun.
(2016) - et al.
Cancer pain relief achieved by disrupting tumor-driven semaphorin3A signaling in mice
Neurosci. Lett.
(2016) - et al.
Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors
Cell Stem Cell
(2009) - et al.
Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies
Ther. Adv. Med. Oncol.
(2014) - et al.
Identification of human brain tumour initiating cells
Nature
(2004) - et al.
Cancer drug resistance: an evolving paradigm
Nat. Rev. Cancer
(2013) - et al.
A restricted cell population propagates glioblastoma growth after chemotherapy
Nature
(2012) - et al.
TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia
Nature
(2010)
NKX2.2 suppresses self-renewal of glioma-initiating cells
Cancer Res.
mTORC1 is essential for leukemia propagation but not stem cell self-renewal
J. Clin. Invest.
The semaphorins: versatile regulators of tumour progression and tumour angiogenesis
Nat. Rev. Cancer
Semaphorins and plexins as therapeutic targets
Nat. Rev. Drug Discov.
Cited by (12)
Emerging roles and mechanisms of semaphorins activity in cancer
2023, Life SciencesSemaphorins as Regulators of Phenotypic Plasticity and Functional Reprogramming of Cancer Cells
2019, Trends in Molecular MedicineCitation Excerpt :For example, Sema3C overexpression upregulated the stemness marker CD44 in human prostate cancer cells [19]; moreover, its silencing induced apoptosis in glioma stem cells by hindering Rac1 activation [61]. Surprisingly, also autocrine Sema3A was shown to be crucial for the maintenance of mouse lung cancer cell stemness [62]. In fact, Sema3A downregulation reduced the expression of SOX2 and CD44 stem cell markers and significantly reduced sphere-forming ability.
High glucose up-regulates Semaphorin 3A expression via the mTOR signaling pathway in keratinocytes: A potential mechanism and therapeutic target for diabetic small fiber neuropathy
2018, Molecular and Cellular EndocrinologyCitation Excerpt :Our study showed that mTOR signaling was activated and that Sema3A expression was up-regulated by rSema3A in HaCaT cells. These findings are consistent with previous studies, which showed that the mTOR/4E-BP1 signaling pathway was activated in growth cones by rSema3A (Manns et al., 2012) and that mTOR/p70 S6K signaling was decreased after Sema3A knockdown in Lewis lung carcinoma cells (Yamada et al., 2016b, 2016c). This signaling can be rescued by rSema3A (Yamada et al., 2016b).
Combined analysis of DNA methylation and gene expression profiles of osteosarcoma identified several prognosis signatures
2018, GeneCitation Excerpt :SEMA3A knockdown completely abolished tumorigenicity and the sphere-formation and self-renewal ability of Lewis lung carcinoma stem cells. The Sema3a knockdown was also associated with decreased expression of mRNA for stem cell markers (Yamada et al., 2016). Deng et al. revealed that SEMA3A was involved in OS-related pathways (Deng et al., 2013).
Regulation of Sema3A on oral mesenchymal stem cell function
2023, Chinese Journal of Tissue Engineering Research